ADHD Drug Maker Cingulate Draws Investor Attention; Stock Up Over 60% In Seven Months

Attention Deficit/Hyperactivity Disorder (ADHD) is one of the most common childhood disorders and can persist through adolescence and into adulthood. It is characterized by difficulty maintaining focus and attention, challenges with impulse control, and hyperactivity (Source: National Institute of Health). More than 6 million (9.4 per cent) of children in the U.S. have an ADHD diagnosis, according to reports.

Several medications are approved for the treatment of ADHD and are classified as either stimulants or non-stimulants. Research indicates that stimulant medications are the most effective and are typically used as first-line treatment for managing ADHD symptoms. However, most currently available extended-release formulations of Stimulants require multiple doses per day and often fail to provide consistent coverage across the entire active day.

Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe Now
Already subscribed? Sign in

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com